<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Saga</title>
	<atom:link href="http://www.tapanray.in/tag/saga/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>India’s Drug Quality Concerns: Is Light At The End of The Tunnel In Sight Now?</title>
		<link>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now</link>
		<comments>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/#comments</comments>
		<pubDate>Mon, 07 Aug 2023 00:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[action]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[end]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[light]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[QR]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tunnel]]></category>
		<category><![CDATA[two=pronged]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10805</guid>
		<description><![CDATA[A brief chronology of some recent events on issues pertaining to patient-health-safety with drugs, as captured below, would possibly generate a mixed feeling for many. This includes a serious concern about, especially generic drug quality safety standards in India, on the one &#8230; <a href="http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>On The Flip Side of Pharma Industry: A Saga of Perennial Contradictions</title>
		<link>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions</link>
		<comments>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/#comments</comments>
		<pubDate>Mon, 09 Dec 2019 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CEOs]]></category>
		<category><![CDATA[contradiction]]></category>
		<category><![CDATA[contradictions]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[facet]]></category>
		<category><![CDATA[flip]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[perennial]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[primary]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[Senate]]></category>
		<category><![CDATA[shift]]></category>
		<category><![CDATA[side]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vice versa]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9804</guid>
		<description><![CDATA[Awesome contribution in the battle against multiple diseases, is obviously the primary facet of the pharma industry. However, on its flip side, one would witness a saga of numerous contradictions. Some of these exist perennially in well-protected opaque cocoons, regardless &#8230; <a href="http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>MNCs to Challenge MNC Patents in India: Boon for Patients?</title>
		<link>http://www.tapanray.in/mncs-to-challenge-mnc-patents-in-india-boon-for-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=mncs-to-challenge-mnc-patents-in-india-boon-for-patients</link>
		<comments>http://www.tapanray.in/mncs-to-challenge-mnc-patents-in-india-boon-for-patients/#comments</comments>
		<pubDate>Mon, 16 Sep 2013 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[BDR]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[boon]]></category>
		<category><![CDATA[Brazil]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[deep]]></category>
		<category><![CDATA[frivolous]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[highest]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indonesia]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[Kabi]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[laws]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Mylan. Frsenius]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pocket]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[protests. patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revocation]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[South]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Thiland]]></category>
		<category><![CDATA[weak]]></category>
		<category><![CDATA[winds]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3650</guid>
		<description><![CDATA[Close on the heels of a reasonably successful patent challenge by the German pharma Multinational Corporation (MNC) Fresenius Kabi for the breast cancer drug Tykerb of GlaxoSmithKline (GSK) in India, another MNC Mylan, with its headquarter in the United states, &#8230; <a href="http://www.tapanray.in/mncs-to-challenge-mnc-patents-in-india-boon-for-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/mncs-to-challenge-mnc-patents-in-india-boon-for-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDC Saga: Defiant Manufacturers, Sloppy Regulators and Humongous Inaction</title>
		<link>http://www.tapanray.in/fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction</link>
		<comments>http://www.tapanray.in/fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction/#comments</comments>
		<pubDate>Mon, 15 Jul 2013 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[attractiveness]]></category>
		<category><![CDATA[bioequivalence]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Combination]]></category>
		<category><![CDATA[controller]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[D&C]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[DGHS]]></category>
		<category><![CDATA[Dose]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[dubious]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[handsome]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[humongous]]></category>
		<category><![CDATA[inaction]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[madras]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pioglitazone]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[retraction]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[scenario]]></category>
		<category><![CDATA[slack]]></category>
		<category><![CDATA[sloppy]]></category>
		<category><![CDATA[State]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2921</guid>
		<description><![CDATA[&#8220;TO SIN BY SILENCE WHEN THEY SHOULD PROTEST MAKES COWARDS OF MEN&#8221;       &#8211; Abraham Lincoln The ghost of untested, irrational and even of bizarre kind of Fixed Dose Combination (FDC) drugs, which continue to be launched, promoted, prescribed &#8230; <a href="http://www.tapanray.in/fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Old is Always Not Gold&#8217;: The Saga of Uncertainty on the New Drug Policy Continues</title>
		<link>http://www.tapanray.in/old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues</link>
		<comments>http://www.tapanray.in/old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues/#comments</comments>
		<pubDate>Mon, 19 Nov 2012 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Always]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Continues]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[gold]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[uncertainty]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1066</guid>
		<description><![CDATA[Along with the initiation of globalization process of India in 1991, many significant reform oriented steps are being taken by the Government for the pharmaceutical industry as its growth booster. In tandem with gradual reduction in the span of price &#8230; <a href="http://www.tapanray.in/old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
